The David Sinclair NAD+ story — hype, evidence, honest assessment

The protein that made all of this relevant to everyday consumers, twenty years later, was NAD+. Because sirtuin activity requires NAD+ as a cosubstrate. And because NAD+ declines with age. If sirtuins were the engine of cellular resilience, NAD+ was a fuel they needed, a fuel that was running low, and a fuel that — in principle — could be replenished.

This is the origin story of the NAD+ consumer category: not primarily a discovery in NAD+ biology per se, but a convergence between sirtuin research and the observation that the cofactor sirtuins depend on declines with age. Sinclair's lab at Harvard, where he moved after his postdoc, produced a steady stream of research over the following decades that extended the sirtuin story from yeast to mice to mammals, linked it to caloric restriction and the aging-CR connection that had fascinated longevity researchers since the 1930s, and eventually framed NAD+ as a potentially targetable node in the aging process.

The mouse results were striking, and this is where the honest history requires holding two things simultaneously. In aged mice, NMN supplementation produced improvements across a remarkable range of aging-related phenotypes: better energy metabolism, preserved muscle function, improved bone density, better vascular health, improved endurance, partial reversal of some age-related cognitive decline. These weren't small or equivocal effects. They were the kind of results that, in a model organism, would get researchers very excited — and they did. The Imai and Sinclair groups both produced work in this period that pointed toward NAD+ precursor supplementation as one of the more compelling interventions in the aging biology toolkit.

The problem — and it's a real one — is that mouse aging models have historically been poor predictors of human longevity outcomes. Mice are not small humans. Their lifespans are so short, and their biology in important respects so different, that interventions that robustly extend mouse lifespan or mouse healthspan have often failed to translate. Resveratrol, which was one of the earlier Sinclair longevity compounds (it was found to activate SIRT1), produced dramatic results in mice on high-fat diets and attracted enormous popular attention in the mid-2000s. The controlled human trial results were considerably less dramatic. The resveratrol story is a useful template for thinking about the NAD+ story: the basic science was real, the mechanisms were real, the mouse results were real, and the human clinical translation has been more limited than the early enthusiasm implied.

Sinclair's book Lifespan, published in 2019, brought his framework for aging — the Information Theory of Aging, which proposes that aging is fundamentally an epigenetic phenomenon driven by the loss of epigenetic information in response to DNA damage, with sirtuins as the responders and NAD+ as the resource they consume doing it — to a mainstream audience. The book was well-written and genuinely intellectually serious in places. It was also commercially positioned in ways that made some of his peers uncomfortable. The chapter on what Sinclair himself takes — NMN, resveratrol, metformin — appeared in the context of a book arguing that aging is a disease and can be treated, which gave it a how-I'm-reversing-my-aging flavor that critics argued went well ahead of the evidence.

The media amplification of Sinclair's work has been enormous and, at times, somewhat disconnected from the actual evidence base. His appearances on Joe Rogan's podcast and others reached millions of people who had not read a scientific paper in their lives. What they heard — in simplified form — was: longevity researcher at Harvard takes NMN every day and believes it's meaningfully extending his health, sirtuins are the master aging regulators, NAD+ is the key, here's what I do. The consumer supplement market responded accordingly. NMN sales grew dramatically in the years following the book's publication; multiple companies formed specifically around NMN formulations, some of them founded by people in Sinclair's orbit or citing his research.

This created a feedback loop that made dispassionate evaluation difficult. The demand for NMN grew faster than the clinical evidence did. Companies citing Sinclair's research sold products at premium prices. Sinclair himself had financial relationships with some of the companies in this space — disclosed, but present — which critics used to raise questions about conflicts of interest. The criticism wasn't that the underlying science was fabricated; it was that the distance between "promising mouse data and plausible mechanisms" and "supplement that will change your aging trajectory" was being navigated too casually, with commercial interests providing incentive to narrow that distance rhetorically faster than the data warranted.

The 2022 episode that became known as the "biological age reversal" controversy is worth examining as a specific case study. Sinclair posted on social media that his biological age — as measured by epigenetic clocks — had reversed meaningfully over recent years, attributing this in part to his longevity protocol. The post generated enormous engagement and was widely interpreted as a personal demonstration of what NAD+ supplementation and other longevity interventions could achieve. Critics pointed out multiple problems: epigenetic clocks are a research tool with significant measurement variability and debated validity as a true measure of biological age; a single person's self-reported data without controls is not evidence of anything about the intervention; and the public communication implied a causal relationship between Sinclair's specific practices and his clock results that the data couldn't support. Sinclair pushed back on the characterization while standing by the underlying science. The episode illustrated the tension between researcher-as-public-communicator and researcher-as-scientist.

Separately from the public communication controversy, it's worth stating clearly what the underlying biology does and doesn't support. Sirtuin biology is real. The SIRT1, SIRT3, SIRT6 research is substantial, peer-reviewed, and replicated across labs. The role of NAD+ as a sirtuin cofactor is not in question. The age-associated NAD+ decline has been documented in humans. NMN and NR supplementation raises NAD+ in human blood — this is demonstrated in controlled trials. The connections between NAD+ decline, sirtuin hypoactivity, and multiple aging-associated phenotypes in mouse models are well-established. None of this is Sinclair's invention, but his lab contributed meaningfully to much of it, and his synthesis of these threads into a coherent theoretical framework was genuinely valuable for the field.

What hasn't been established in humans: that raising NAD+ through supplementation produces the sirtuin-mediated effects that the mouse work predicts, at the doses used in human supplementation. That the cognitive improvements, metabolic improvements, and body composition changes seen in aged mice translate meaningfully to humans. That any of this extends human lifespan or even meaningfully extends human healthspan, as opposed to making people with NAD+ deficits feel better while the underlying question about longevity remains open.

The critical scientists in this space — including Charles Brenner, who has the longest track record on NR and has been consistently willing to push back on exaggerated claims, including from Sinclair's direction — have maintained that the mechanistic work is compelling and the clinical evidence is early and incomplete. Brenner's position is essentially: NR raises NAD+, NAD+ matters, the mouse data is interesting, the human data is preliminary, and the claims made in the popular press about what this means for human longevity are ahead of what has been demonstrated. This position is not anti-NAD+; it's a scientist asking for the evidence to catch up with the enthusiasm.

How should consumers think about NAD+ separately from the marketing and the celebrity researcher persona? The most useful frame is one that separates what we know at different levels of certainty. At the mechanistic level — NAD+ is important, sirtuins matter, the decline with age is real — the science is solid. At the preclinical level — mouse results — the evidence is genuinely compelling, while carrying the translation caveat that this class of result has a mixed human track record. At the human clinical level — controlled trials showing meaningful outcomes in aging endpoints — the evidence is early and evolving. Several human trials of NMN and NR for metabolic function, muscle aging, and cardiovascular aging have shown modest positive results. Large, long-duration human trials showing effects on aging trajectory don't yet exist.

The honest conclusion is that the Sinclair NAD+ story is an unusually effective combination of real science, compelling theory, skilled public communication, and commercial momentum. The real science is not nothing. The theory is biologically serious, not speculative junk. The distance between where the evidence is and where the marketing positioned it has been real and worth acknowledging. The trajectory of the field — more human trials, more mechanistic characterization, better outcome measures — is moving in the direction of closing that gap. Where it lands will not be determined by the podcast appearances or the supplement sales. It will be determined by the clinical trials, and those are still running.